Triple-leveraged ETFs aren’t for everyone, but if you believe biotech is about to break out, Direxion Daily S&P Biotech Bull ...
Moderna now anticipates ending 2025 with cash and cash equivalents worth $8.1 billion, up from its previous forecast of ...
Moderna CEO Stéphane Bancel positions 2026 as a catalyst-rich year driven by new vaccine launches, late-stage oncology data, ...
Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 ...
11d
Moderna Announces Global Regulatory Submissions for Its Investigational Seasonal Influenza Vaccine
Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS ...
Stéphane Bancel, CEO of vaccine maker Moderna, addressed shareholders in a letter that dissected the events of 2025 while ...
Expects 2025 revenue of approximately $1.9 billion (unaudited), $100 million above midpoint communicated on 3Q25 Earnings CallImproves 2025 expected GAAP operating expenses by $200 million since 3Q25 ...
SAN FRANCISCO — Despite all the hopeful chatter about the life sciences industry making a rebound after a multiyear ...
Moderna has filed for marketing authorization in the U.S., EU, Canada and Australia for mRNA-1010 CAMBRIDGE, MA / ACCESS Newswire / January 5, 2026 / Moderna, Inc. (NASDAQ:MRNA) today provided an upda ...
Initiate Moderna with a Hold rating at a $25 target price (lower than the current price), citing balanced risk-reward despite the advanced mRNA platform and robust pipeline. MRNA's near-term execution ...
(The Hill) — The Food and Drug Administration (FDA) expanded the approval of Moderna’s RSV vaccine late Thursday to include individuals 18-59 years of age who are at increased risk for severe illness ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback